ACM
VKTX icon

Accent Capital Management’s Viking Therapeutics VKTX Stock Holding History

Accent Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-66
Closed -$2.66K – 338
2024
Q4 		$2.66K Sell
66
-33
-33% -$1.88K ﹤0.01% 179
2024
Q3 		$6.27K Buy
+99
New +$5.81K ﹤0.01% 186

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Accent Capital Management's VKTX Position: Q1 2025 in Review

Accent Capital Management sold out of Viking Therapeutics (VKTX) in Q1 2025, closing a stake of 66 shares — an estimated $2.66K sold.

Accent Capital Management first reported a position in VKTX in Q3 2024 and held it in 2 quarters. The position peaked at $6.27K in Q3 2024. 372 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

  • Accent Capital Management reported no remaining Viking Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Accent Capital Management sold 66 Viking Therapeutics shares in Q1 2025, an estimated $2.66K.
  • Accent Capital Management first reported a position in Viking Therapeutics in Q3 2024 and held it in 2 quarters.
  • Accent Capital Management's Viking Therapeutics position peaked at $6.27K in Q3 2024.
  • 372 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on Accent Capital Management's 13F filing for Q1 2025, filed 9 May 2025.